5-amino-cyclooctanol | 90226-60-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-amino-cyclooctanol
• 英文别名: 5-Aminocyclooctan-1-ol
• CAS: 90226-60-1
• 化学式: C₈H₁₇NO
• mdl: MFCD19205352
• 分子量: 143.229
• InChiKey: GHLYOGUPTIVVGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-amino-cyclooctanol 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 生成 1-(5-羟基-环辛基)-4-羟甲基-3,3-二甲基-吡咯烷-2-酮
  参考文献：
  名称：

  WO2007/118185

  摘要：

  公开号：
• 作为产物：
  描述：

  5-羟基环辛酮 在 氨 、 镍 作用下， 生成 5-amino-cyclooctanol
  参考文献：
  名称：

  DE1077658

  摘要：

  公开号：

文献信息

• INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：Yeh S. Vince

  公开号：US20080076819A1

  公开（公告）日：2008-03-27

  A compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  化合物式(I)的复合物，或其药学上可接受的盐、前药、前药的盐或其组合物。抑制11-β-羟基类固醇脱氢酶1型酶的方法。治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和情况的方法。
• CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES
  申请人：PLETTENBURG Oliver

  公开号：US20100056518A1

  公开（公告）日：2010-03-04

  The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  本发明涉及公式（I）的6-取代异喹啉衍生物，用于治疗和/或预防与Rho-激酶和/或Rho-激酶介导的肌球蛋白轻链磷酸酶磷酸化相关的疾病，以及含有此类化合物的组合物。
• Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme
  申请人：Yeh Vince S.

  公开号：US20080312214A1

  公开（公告）日：2008-12-18

  Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  治疗患有糖皮质激素相关疾病和症状的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶类型1酶活性的选择性抑制剂，其中该抑制剂是式(I)的化合物，或其药学上可接受的盐、前药盐、前药盐的盐或其组合。抑制11-β-羟基类固醇脱氢酶类型1酶的方法。治疗神经退行性、功能障碍、急性精神病、焦虑、痴呆、抑郁、非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合症以及其他由过度糖皮质激素作用介导的疾病和症状的方法。
• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Abbott Laboratories

  公开号：US07737137B2

  公开（公告）日：2010-06-15

  Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  治疗患有糖皮质激素相关疾病和病况的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶类型1酶活性的选择性抑制剂，其中抑制剂是化合物I的药物接受性盐、前药、前药的盐或其组合。抑制11-β-羟基类固醇脱氢酶类型1酶的方法。治疗神经退行性、功能障碍、急性精神病、焦虑、痴呆、抑郁、非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和病况的方法。
• Cycloalkylamine substituted isoquinolone derivatives
  申请人：Plettenburg Oliver

  公开号：US08742116B2

  公开（公告）日：2014-06-03

  The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  本发明涉及式(I)的6-取代异喹啉衍生物，用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶磷酸化有关的疾病，以及含有这种化合物的组合物。